[Drugs in shock treatment] Internist (Berl). [Article in German] Authors R H Dietzman, G J Motsay, R C Lillehei. It is a major, and frequently fatal, complication of a variety of acute and chronic disorders, occurring most commonly following acute myocardial infarction (MI). PCI should be initiated within 90 minutes of presentation; however, it remains helpful, as an acute intervention, within 12 hours of presentation. 1971 Mar;12(3):103-7. Pharmacologic support of the patient with cardiogenic shock plays a major role in clinical management. Cardiogenic shock is a physiologic state in which inadequate tissue perfusion results from cardiac dysfunction, most often systolic. Cardiogenic shock (CS) is a hemodynamically complex syndrome characterized by a low cardiac output that often culminates in multiorgan system failure and death. Treatments include medicines, heart procedures, and medical devices to support or restore blood flow in the body and prevent organ damage. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Coronary cardiogenic shock is more common than non coronary cardiogenic shock and is seen most often in patients with acute myocardial infarction. Data sources include IBM Watson Micromedex (updated 2 Feb 2021), Cerner Multum™ (updated 3 Feb 2021), ASHP (updated 29 Jan … Cardiogenic shock is life-threatening and requires rapid diagnosis and identification of the cause, and emergency medical treatment. Noncoronary. Cardiogenic shock occurs when adequate oxygen and nutrient delivery to the organs and tissues of the body is compromised as a direct result of myocardial dysfunction. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. One challenge of guidelines is that the way recommendations are stated can potentially lead to oversimplification of complex situations. Noncoronary cardiogenic shock is related to conditions that stress the myocardium as well as conditions that result in an ineffective myocardial function. In other words, there is a failure of the heart to effectively pump blood. Despite recent advances, clinical outcomes remain poor, with mortality rates exceeding 40%. Cardiogenic shock (CS) is a clinical condition of inadequate tissue(end organ) perfusion due to cardiac dysfunction • Hypotension (SBP < 80-90 mmHg) or MAP 30 mmHg below baseline • Reduced cardiac index(<1.8 L/min per m2) <2.0-2.2 L/min per m2 with support • Adequate or elevated filling pressures Dopamine (3,4 dihydroxy phenylethylamine) is a naturally occurring catecholamine that has been employed both experimentally and clinically for the therapy of various forms of shock. The SHOCK trial demonstrated that either PCI or CABG is the treatment of choice for cardiogenic shock and that each has been shown to markedly decrease mortality rates at 1 year. Diuretics, inotropic agents, and vasodilator drugs all have a place in the management of selected patients with low output states and cardiogenic shock following myocardial infarction. Below is a list of common medications used to treat or reduce the symptoms of cardiogenic shock. It functions as an a … Scientific statements and publications have recommended the use of vasoconstrictors as the first-line pharmacologic choice for most cases of cardiogenic shock (CS), without the abundance of strong clinical evidence. Dopamine possesses a variety of useful pharmacologic properties.